– Clinicians agree that evidence supports testing benefits for all – SAN FRANCISCO, Sept. 15, 2022 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, joined other clinical experts in releasing a new commentary in Journal of Clinical Oncology Precision Oncology,…